The place of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Panic disorder is a frequently chronic condition with extensive patterns of psychiatric comorbidity. Optimum pharmacotherapy with traditional agents is limited by side effects, long-term tolerability, and other problems. Recent research findings support the characterization of panic disorder as an illness involving derangements of central serotonergic function. Selective serotonin reuptake inhibitors could become first-line treatment of the disorder, as they seem to have fewer side effects than tricyclic antidepressants and benzodiazepines.